{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:10:05Z","timestamp":1793333405092,"version":"4.5.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":1563,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Projekt DEAL"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Therapeutic options for patients with heart failure with preserved ejection fraction (HFpEF) are sparse. Mitral regurgitation (MR) is a common feature of HFpEF and worsens heart failure symptoms and prognosis. Our study examines the outcome of patients with preserved left ventricular ejection fraction (LVEF) and elevated left atrial (LAP) or left ventricular filling pressures (LVEDP), indicative of HFpEF, after undergoing percutaneous edge-to-edge mitral valve repair (pMVR) for moderate\u2013severe MR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Two hundred eleven patients with preserved LVEF (&amp;gt;50%), who underwent pMVR, were dichotomized by LAP (&amp;lt;\u2009\/\u2009\u226515 mmHg) and LVEDP (&amp;lt;\u2009\/\u2009\u226516 mmHg). Forty-nine per cent of patients showed elevated LAP, and LVEDP was elevated in 55%, both indicating HFpEF. Patients with elevated filling pressures featured typical clinical characteristics of HFpEF, higher N-terminal pro-brain natriuretic peptide levels (5544.9 pg\/mL in high LAP group vs. 3071.7 pg\/mL in normal LAP group, P = 0.06; 5061.0 pg\/mL in high LVEDP group vs. 3230.3 pg\/mL in normal LVEDP group, P = 0.08), and higher prevalence of pulmonary hypertension (mean pulmonary artery pressure 36.4 mmHg in high LAP group vs. 26.3 mmHg in normal LAP group, P &amp;lt; 0.001; 35.2 mmHg in high LVEDP group vs. 29.7 mmHg in normal LVEDP group, P = 0.004) and atrial fibrillation (78.8% in normal LAP group vs. 61.0% in high LAP group, P = 0.04; 75.3% in high LVEDP group vs. 67.5% in normal LVEDP group, P = 0.25). Pre-treatment MR grade and New York Heart Association (NYHA) class were similar in both normal filling pressure and HFpEF groups. pMVR in HFpEF patients achieved effective heart failure symptom relief comparable with patients with normal filling pressures: significant decrease of MR grade and NYHA class, as well as significant reduction of heart failure hospitalizations 12 months after compared with 12 months before MitraClip.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Percutaneous edge-to-edge mitral valve repair for moderate\u2013severe MR is an effective treatment option for symptom relief in HFpEF patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.13561","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T03:11:53Z","timestamp":1631157113000},"page":"5010-5021","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Percutaneous Edge-to-Edge Mitral Valve Repair for Mitral Regurgitation Improves Heart Failure Symptoms in Heart Failure with Preserved Ejection Fraction Patients"],"prefix":"10.1093","volume":"8","author":[{"given":"Matthias","family":"Gr\u00f6ger","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, University of Ulm , Albert-Einstein-Allee 23, Ulm, 89081 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinny Karin","family":"Scheffler","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University of Ulm , Albert-Einstein-Allee 23, Ulm, 89081 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Sch\u00f6sser","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University of Ulm , Albert-Einstein-Allee 23, Ulm, 89081 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonhard Moritz","family":"Schneider","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University of Ulm , Albert-Einstein-Allee 23, Ulm, 89081 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Rottbauer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University of Ulm , Albert-Einstein-Allee 23, Ulm, 89081 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinisa","family":"Markovic","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University of Ulm , Albert-Einstein-Allee 23, Ulm, 89081 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"Ke\u00dfler","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University of Ulm , Albert-Einstein-Allee 23, Ulm, 89081 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,9,9]]},"reference":[{"key":"2026012114195606700_ehf213561-bib-0001","doi-asserted-by":"crossref","first-page":"i26","DOI":"10.1093\/ejcts\/ezy410","article-title":"The role of transcatheter mitral valve therapy in heart failure","volume":"55","author":"Treede","year":"2019","journal-title":"Eur J Cardiothorac Surg"},{"key":"2026012114195606700_ehf213561-bib-0002","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","article-title":"2017 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"38","author":"Baumgartner","year":"2017","journal-title":"Eur Heart J"},{"key":"2026012114195606700_ehf213561-bib-0003","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","article-title":"Transcatheter mitral-valve repair in patients with heart failure","volume":"379","author":"Stone","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012114195606700_ehf213561-bib-0004","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1016\/j.jacc.2019.02.061","article-title":"Atrial functional mitral regurgitation: JACC Review Topic of the Week","volume":"73","author":"Deferm","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026012114195606700_ehf213561-bib-0005","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/echo.14249","article-title":"Mechanistic insights into atrial functional mitral regurgitation: far more complicated than just left atrial remodeling","volume":"36","author":"Silbiger","year":"2019","journal-title":"Echocardiography"},{"key":"2026012114195606700_ehf213561-bib-0006","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/ejhf.1699","article-title":"Functional mitral regurgitation and left atrial myopathy in heart failure with preserved ejection fraction","volume":"22","author":"Tamargo","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114195606700_ehf213561-bib-0007","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/ejhf.562","article-title":"Functional mitral regurgitation at discharge and outcomes in patients hospitalized for acute decompensated heart failure with a preserved or reduced ejection fraction","volume":"18","author":"Kajimoto","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012114195606700_ehf213561-bib-0008","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","article-title":"A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction","volume":"138","author":"Reddy","year":"2018","journal-title":"Circulation"},{"key":"2026012114195606700_ehf213561-bib-0009","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/ejhf.1741","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA\u2013PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"22","author":"Pieske","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114195606700_ehf213561-bib-0010","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/ejhf.1289","article-title":"Predictors of rehospitalization after percutaneous edge-to-edge mitral valve repair by MitraClip implantation","volume":"21","author":"Ke\u00dfler","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012114195606700_ehf213561-bib-0011","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jacc.2015.05.049","article-title":"Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions: a consensus document from the Mitral Valve Academic Research Consortium","volume":"66","author":"Stone","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026012114195606700_ehf213561-bib-0012","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.jacc.2005.07.065","article-title":"Percutaneous mitral valve repair using the edge-to-edge technique: six-month results of the EVEREST Phase I Clinical Trial","volume":"46","author":"Feldman","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2026012114195606700_ehf213561-bib-0013","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3399\/bjgp16X687649","article-title":"Time for correct diagnosis and categorisation of heart failure in primary care","volume":"66","author":"Deaton","year":"2016","journal-title":"Br J Gen Pract"},{"key":"2026012114195606700_ehf213561-bib-0014","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012114195606700_ehf213561-bib-0015","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1007\/s00380-019-01393-2","article-title":"Prognostic significance of high-sensitive cardiac troponin in patients with heart failure with preserved ejection fraction","volume":"34","author":"Suzuki","year":"2019","journal-title":"Heart Vessels"},{"key":"2026012114195606700_ehf213561-bib-0016","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1136\/heartjnl-2018-314173","article-title":"Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction","volume":"105","author":"Salah","year":"2019","journal-title":"Heart"},{"key":"2026012114195606700_ehf213561-bib-0017","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamacardio.2016.4726","article-title":"Factors associated with and prognostic implications of cardiac troponin elevation in decompensated heart failure with preserved ejection fraction: findings from the American Heart Association Get With The Guidelines-Heart Failure program","volume":"2","author":"Pandey","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2026012114195606700_ehf213561-bib-0018","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.amjcard.2019.07.065","article-title":"Incidence of, associations with and prognostic impact of worsening renal function in heart failure with different ejection fraction categories","volume":"124","author":"L\u00f6fman","year":"2019","journal-title":"Am J Cardiol"},{"key":"2026012114195606700_ehf213561-bib-0019","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/ajh\/hpz108","article-title":"H2PEF score as a prognostic value in HFpEF patients","volume":"32","author":"Sueta","year":"2019","journal-title":"Am J Hypertens"},{"key":"2026012114195606700_ehf213561-bib-0020","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1161\/CIRCHEARTFAILURE.113.000823","article-title":"Pulmonary hypertension in heart failure preserved ejection fraction","volume":"7","author":"Guazzi","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026012114195606700_ehf213561-bib-0021","first-page":"102","article-title":"Haemodynamics of heart failure with preserved ejection fraction: a clinical perspective","volume":"2","author":"Gori","year":"2016","journal-title":"Card Fail Rev"},{"key":"2026012114195606700_ehf213561-bib-0022","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1093\/eurheartj\/ehu193","article-title":"Right heart dysfunction in heart failure with preserved ejection fraction","volume":"35","author":"Melenovsky","year":"2014","journal-title":"Eur Heart J"},{"key":"2026012114195606700_ehf213561-bib-0023","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.amjcard.2013.01.300","article-title":"One- and twelve-month safety and efficacy outcomes of patients undergoing edge-to-edge percutaneous mitral valve repair (from the GRASP Registry)","volume":"111","author":"Grasso","year":"2013","journal-title":"Am J Cardiol"},{"key":"2026012114195606700_ehf213561-bib-0024","first-page":"E275","article-title":"The MitraClip Asia-Pacific registry: differences in outcomes between functional and degenerative mitral regurgitation","volume":"87","author":"Tay","year":"2016","journal-title":"Catheter Cardiovasc Interv"},{"key":"2026012114195606700_ehf213561-bib-0025","first-page":"145","article-title":"Percutaneous mitral valve repair in primary compared with secondary mitral valve regurgitation using the Mitral Valve Academic Research Consortium criteria","volume":"29","author":"Seeger","year":"2017","journal-title":"J Invasive Cardiol"},{"key":"2026012114195606700_ehf213561-bib-0026","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.athoracsur.2009.11.032","article-title":"EuroSCORE performance in valve surgery: a meta-analysis","volume":"89","author":"Parolari","year":"2010","journal-title":"Ann Thorac Surg"},{"key":"2026012114195606700_ehf213561-bib-0027","first-page":"455","article-title":"Performance of the EuroSCORE II and the Society of Thoracic Surgeons Score in patients undergoing aortic valve replacement for aortic stenosis","volume":"56","author":"Kuwaki","year":"2015","journal-title":"J Cardiovasc Surg (Torino)"},{"key":"2026012114195606700_ehf213561-bib-0028","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012114195606700_ehf213561-bib-0029","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"2026012114195606700_ehf213561-bib-0030","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13561","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13561","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/6\/5010\/65569967\/eschf_8_6_5010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/6\/5010\/65569967\/eschf_8_6_5010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:23:58Z","timestamp":1769023438000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/8\/6\/5010\/8343744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,9]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,9,9]]},"published-print":{"date-parts":[[2021,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13561","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12]]},"published":{"date-parts":[[2021,9,9]]},"assertion":[{"value":"2020-09-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}